8-K: Insperity Reports Q3 Loss, Extends UHC Contract

Insperity, Inc. announced a net loss for Q3 2025 and updated its full-year guidance, while also securing a multi-year extension with UnitedHealthcare for cost savings and reduced risk.

Summary

• Insperity, Inc. reported a net loss of $20 million for the third quarter ended September 30, 2025, compared to a net income of $3 million in Q3 2024.
• Diluted EPS for Q3 2025 was $(0.53), a significant decrease from $0.07 in Q3 2024.
• Adjusted EBITDA for Q3 2025 was $10 million, down 74% from $39 million in Q3 2024.
• Revenues increased 4% year-over-year to $1.6 billion in Q3 2025, driven by a 1% increase in average paid WSEEs to 312,842 and a 3% increase in revenue per WSEE.
• Gross profit decreased 15% to $195 million in Q3 2025, primarily due to higher-than-expected benefits costs from elevated inpatient, outpatient, pharmacy trends, and large claim activity.
• The company extended its medical coverage arrangement with UnitedHealthcare through 2028, which is expected to provide additional cost savings starting in 2026.
• The UHC amendment allows Insperity to annually elect to limit its responsibility for participant claim costs to $500,000, $750,000, or $1,000,000 per year, reducing large claims risk.
• Insperity officially rolled out HRScale, its strategic joint solution with Workday, which is expected to be a catalyst for future growth.
• Year-to-date 2025, Insperity returned $87 million to shareholders through $19 million in share repurchases (225,000 shares) and $68 million in cash dividends.
• Updated full-year 2025 guidance projects average WSEEs paid between 310,200 and 310,700, adjusted EPS between $0.84 and $1.47, and adjusted EBITDA between $119 million and $153 million.

Sentiment

Score: 4

Explanation: The sentiment is moderately negative due to significant financial underperformance in Q3 2025 and a downward revision of full-year guidance. While the UnitedHealthcare contract extension and HRScale rollout are positive strategic developments, their impact is future-oriented, and current results reflect substantial challenges from elevated healthcare costs.

Positives

• The multi-year contract extension with UnitedHealthcare through 2028 is expected to provide significant cost savings and reduce large claims risk by offering options to limit responsibility for participant claim costs to $500,000, $750,000, or $1,000,000 per year starting January 1, 2026.
• The official rollout of HRScale, a strategic joint development offering with Workday, is underway and positioned to be a catalyst for future growth and unique market positioning.
• Operating expenses decreased 4% in Q3 2025 to $220 million and 1% year-to-date to $692 million, demonstrating some cost management efforts.
• The company returned $87 million to shareholders during the first nine months of 2025 through share repurchases ($19 million for 225,000 shares) and cash dividends ($68 million).

Negatives

• Insperity reported a net loss of $20 million in Q3 2025, a significant decline from a net income of $3 million in Q3 2024.
• Diluted EPS for Q3 2025 was $(0.53), a substantial decrease from $0.07 in the prior year quarter.
• Adjusted EBITDA decreased 74% to $10 million in Q3 2025 from $39 million in Q3 2024.
• Gross profit declined 15% to $195 million in Q3 2025, primarily due to higher-than-expected benefits costs driven by elevated inpatient, outpatient, and pharmacy trends, as well as increased frequency of large claim activity.
• Year-to-date net income decreased 74% to $26 million, and adjusted EBITDA decreased 42% to $144 million compared to the same period in 2024.
• The updated 2025 guidance projects significant year-over-year decreases in adjusted EPS (59%-77%) and adjusted EBITDA (43%-61%) for the full year, indicating continued financial challenges.

Risks

• Adverse economic conditions could negatively impact business operations and financial performance.
• Failure to comply with or meet client expectations regarding certain COVID-19 relief programs, including the federal employee retention tax credit program.
• Bank failures or other events affecting financial institutions could disrupt operations.
• Labor shortages, increasing competition for highly skilled workers, and evolving employee expectations regarding the workplace.
• Impact of inflation and changes in U.S. trade policy.
• Vulnerability to regional economic factors due to geographic market concentration.
• Failure to comply with covenants under the credit facility.
• Impact of a future outbreak of highly infectious or contagious disease.
• Liability for worksite employee (WSEE) payroll, payroll taxes, and benefits costs, or other liabilities associated with actions of client companies or WSEEs, including if clients fail to pay.
• Increases in health insurance costs and workers' compensation rates and underlying claims trends, healthcare reform, financial solvency of workers' compensation carriers, other insurers or financial institutions, state unemployment tax rates, and liabilities for employee and client actions or payroll-related claims.
• An adverse determination regarding Insperity's status as the employer of its WSEEs for tax and benefit purposes and an inability to offer alternative benefit plans following such a determination.
• Cancellation of client contracts on short notice, or the inability to renew client contracts or attract new clients.
• The ability to secure competitive replacement contracts for health insurance and workers' compensation insurance at the expiration of current contracts.
• Regulatory and tax developments and possible adverse application of various federal, state, and local regulations.
• Failure to manage growth of operations and the effectiveness of sales and marketing efforts.
• The impact of the competitive environment and other developments in the human resources services industry, including the professional employer organization (PEO) industry, on growth and/or profitability.
• An adverse final judgment or settlement of claims against Insperity.
• Disruptions of information technology systems or failure to enhance service and technology offerings to address new regulations or client expectations.
• Liability or damage to reputation relating to disclosure of sensitive or private information as a result of data theft, cyberattacks, or security vulnerabilities.
• Failure of third-party providers, such as financial institutions, data centers, or cloud service providers.
• Ability to fully realize the anticipated benefits of the strategic partnership and joint solution with Workday, Inc.
• Ability to integrate or realize expected returns on future product offerings, including through acquisitions, strategic partnerships, and investments.

Future Outlook

Management is actively working to position Insperity for sustainable profitability at normal historical levels, addressing unexpected, elevated healthcare cost trends through assertive actions including the new UnitedHealthcare contract. The company expects the UHC agreement to substantially improve its financial outlook for 2026 and enhance strategic alignment for growth and profitability in subsequent years. The HRScale product rollout with Workday is anticipated to serve as a catalyst for future growth. However, macro pressures affecting the business remain significant, and further work is needed to deliver desired results. The updated 2025 guidance projects continued declines in adjusted EPS and EBITDA for the fourth quarter and full year.

Management Comments

• Paul J. Sarvadi, chairman and chief executive officer, stated: "We are actively working to position Insperity for sustainable profitability at normal historical levels as we execute on our plan in response to unexpected, elevated healthcare cost trend. We are simultaneously taking assertive actions, including through the new contract with UnitedHealthcare, and will continue to focus on attracting and retaining the right clients at the right price and prudently managing expenses."
• Paul J. Sarvadi also commented: "We are also pleased to announce the official rollout of HRScale, our strategic joint development offering with Workday. We believe this offering will position Insperity uniquely within the marketplace and serve as a catalyst for future growth."
• Paul J. Sarvadi further noted: "While we are making progress in the areas we can control, the macro pressures affecting our business remain significant and we recognize there is more work to do to deliver the results we know Insperity can produce."
• James D. Allison, executive vice president of finance, chief financial officer and treasurer, stated: "We are pleased to announce a multi-year contract extension with UnitedHealthcare which provides significant cost reductions and reduces our pooling level for large claims to $500,000 beginning on January 1, 2026. We expect these changes will provide outstanding value for plan participants and help address the challenging employee benefits cost trend environment."
• James D. Allison also added: "We believe the structure of the agreement improves our financial outlook substantially for 2026 and enhances strategic alignment for growth and profitability in subsequent years."

Industry Context

The announcement reflects the broader industry challenge of rising healthcare costs, which Insperity is actively addressing through its extended and amended contract with UnitedHealthcare. This strategic move aims to mitigate financial exposure and secure more favorable terms in a volatile benefits landscape. The rollout of HRScale, a joint solution with Workday, positions Insperity to capitalize on the growing demand for integrated HR technology and services, potentially enhancing its competitive edge against other Professional Employer Organizations (PEOs) and HR solution providers by offering advanced, scalable solutions.

Comparison to Industry Standards

• The filing does not provide specific comparable companies, projects, or results to global benchmarks. It refers to 'normal historical levels' for profitability and 'standard fully-insured large group UnitedHealthcare customers' for rate adjustments, but no explicit industry comparisons are detailed.

Stakeholder Impact

• Shareholders: Negative impact from current financial underperformance and reduced guidance, but potential long-term benefits from strategic initiatives like the UHC contract and HRScale. Share repurchases and dividends provide some return.
• Employees (Worksite Employees): Potential for outstanding value and stability in health benefits due to the extended UnitedHealthcare contract and reduced risk for Insperity.
• Customers (Client Companies): Potential for more stable and cost-effective benefits solutions through the new UHC contract and enhanced HR services via HRScale.
• UnitedHealthcare: Continued and extended partnership, securing a significant client.
• Workday: Continued strategic partnership and rollout of the joint HRScale solution.

Next Steps

• Continue executing the plan to achieve sustainable profitability at normal historical levels.
• Focus on attracting and retaining the right clients at the right price and prudently managing expenses.
• Further develop and integrate the HRScale joint solution with Workday.
• Insperity will make an annual election by December 31st each year regarding the pooling feature and its attachment level with UnitedHealthcare.
• UnitedHealthcare will provide pooling feature charges for 2027 and 2028 by October 15th of the preceding year.

Key Dates

Recommendation

The filing presents a mixed picture. The significant net loss in Q3 2025 and the downward revision of full-year guidance indicate substantial financial headwinds, primarily driven by elevated healthcare costs. This short-term underperformance would typically warrant a 'sell' recommendation. However, the multi-year extension of the UnitedHealthcare contract, which includes expected cost savings and reduced risk through claim pooling, is a crucial strategic positive that improves the financial outlook for 2026 and beyond. Additionally, the rollout of the HRScale solution with Workday offers a promising avenue for future growth and market differentiation. For a seasoned investor, the immediate poor results are concerning, but the proactive strategic measures taken to address core issues and position for future growth suggest that the company is taking necessary steps. Therefore, a 'hold' recommendation is appropriate, allowing time to observe the effectiveness of these strategic initiatives in improving future financial performance, rather than reacting solely to the current negative earnings.

Keywords

Insperity, NSP, SEC Filing, 8-K, Q3 Earnings, Financial Results, UnitedHealthcare, Healthcare Costs, HRScale, Workday, PEO, Human Resources, Benefits Management, Risk Management, Cost Savings, EPS, EBITDA, Revenue, Worksite Employees